Data / Form D filings / Primmune Therapeutics, Inc.
Primmune Therapeutics, Inc.: Form D filings
Primmune Therapeutics, Inc., a pharmaceuticals company in San Diego, CA, filed 6 Form D notices with the SEC between 2017 and 2020. The latest, on November 6, 2020, reports $13 million sold of a $24 million offering to 12 investors.
Find out what Primmune Therapeutics, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- c/o JLABS San Diego, 3210 Merryfield Row, San Diego, CA, 92121
- Phone
- (858) 205-2281
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2017
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1721931
The full lists. Form D filings in California: 5,891 rows, $138.91, or the new rows each week for $19 a month. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Nov 6, 2020 | New notice | $24,000,008 | $13,000,009 | $10,999,999 | 12 | Oct 23, 2020 | sec.gov |
| Mar 17, 2020 | New notice | $3,500,000 | $2,500,000 | $1,000,000 | 2 | Feb 28, 2020 | sec.gov |
| Mar 17, 2020 | New notice | $4,000,000 | $2,000,000 | $2,000,000 | 17 | Feb 4, 2019 | sec.gov |
| Mar 17, 2020 | New notice | $4,000,000 | $1,100,000 | $2,900,000 | 19 | Jul 27, 2018 | sec.gov |
| Jan 30, 2018 | Amendment | $1,525,000 | $1,525,000 | $0 | 36 | Oct 18, 2017 | sec.gov |
| Nov 8, 2017 | New notice | $1,500,000 | $670,000 | $830,000 | 17 | Oct 18, 2017 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Charles McDermott | Executive Officer, Director | |
| James R. Appleman | Executive Officer, Director | |
| Todd J. Harris | Director | |
| Paulo S. Rangel | Executive Officer | |
| Scott S. Morenstein | Director | |
| Andrew S. Rubinstein | Director | |
| Amir S. Nashat | Director |
Other pharmaceuticals companies in California that filed recently
- Anvion Bio, Inc. $100,000 · Oct 7, 2026
- Aqur Biosciences, Inc. $1.5 million · Sep 18, 2026
- BTB Therapeutics, Inc. $8.9 million · Aug 12, 2026
Every Form D from the week of Nov 2, 2020 · All recent filings in California · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Primmune Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.